These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38583785)

  • 1. Systematical mutational analysis of teriparatide on anti-osteoporosis activity by alanine scanning.
    Liang H; Shen H; Zheng M; Shi Y; Li X
    Bioorg Med Chem Lett; 2024 May; 104():129732. PubMed ID: 38583785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
    Bilezikian JP
    Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of osteoporosis with PTH].
    Takeuchi Y
    Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report.
    Javinani A; Aghaei Meybodi HR; Kavosi H
    J Med Case Rep; 2020 Jul; 14(1):87. PubMed ID: 32616027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of PTH in the treatment of osteoporosis.
    Borba VZ; Mañas NC
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid hormone as an anabolic skeletal therapy.
    Rubin MR; Bilezikian JP
    Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation.
    Yamamoto T; Tsujimoto M; Sowa H
    Clin Interv Aging; 2015; 10():1101-9. PubMed ID: 26185429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment.
    Gagnon C; Li V; Ebeling PR
    Clin Interv Aging; 2008; 3(4):635-45. PubMed ID: 19281056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study.
    Nishikawa A; Yoshiki F; Taketsuna M; Kajimoto K; Enomoto H
    Clin Interv Aging; 2016; 11():1653-1659. PubMed ID: 27895472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report.
    Yamamoto T; Taketsuna M; Guo X; Sato M; Sowa H
    J Bone Miner Metab; 2014 Nov; 32(6):699-708. PubMed ID: 24368586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anabolic therapy in glucocorticoid-induced osteoporosis.
    Sambrook PN
    N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
    [No Abstract]   [Full Text] [Related]  

  • 16. A Bone Histomorphometric Analysis of Hypophosphatasia-related Osteoporosis after Teriparatide Treatment.
    Mizuno H; Sawa N; Sekine A; Inoue N; Oba Y; Ikuma D; Yamanouchi M; Hasegawa E; Suwabe T; Suzuki H; Hoshino J; Ubara Y
    Intern Med; 2023 Jan; 62(1):75-79. PubMed ID: 35650135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of parathyroid hormone for the treatment of osteoporosis.
    Miller PD
    Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
    Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
    Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worsening of calcinosis cutis with teriparatide treatment in two osteoporotic patients.
    Echeverri AF; Ospina FE; Cañas CA; Agualimpia A; Suso JP; Tobón GJ; Bonilla-Abadía F
    Br J Dermatol; 2016 Nov; 175(5):1049-1051. PubMed ID: 26992073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
    Sugimoto T; Shiraki M; Fukunaga M; Hagino H; Sone T; Nakano T; Kishimoto H; Ito M; Yoshikawa H; Kishida M; Irie C; Nakamura T
    Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.